Compare Panacea Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x 12.2 23.7 51.5% View Chart
P/BV x 2.9 2.4 121.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
CIPLA
Mar-19
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs364678 53.7%   
Low Rs129484 26.7%   
Sales per share (Unadj.) Rs96.8198.2 48.8%  
Earnings per share (Unadj.) Rs-12.418.5 -67.0%  
Cash flow per share (Unadj.) Rs-2.935.0 -8.2%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs50.4186.3 27.0%  
Shares outstanding (eoy) m61.25805.70 7.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.52.9 86.9%   
Avg P/E ratio x-19.931.4 -63.4%  
P/CF ratio (eoy) x-86.416.6 -520.6%  
Price / Book Value ratio x4.93.1 156.9%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m15,101468,031 3.2%   
No. of employees `0002.522.6 10.9%   
Total wages/salary Rs m1,51628,565 5.3%   
Avg. sales/employee Rs Th2,401.97,053.1 34.1%   
Avg. wages/employee Rs Th614.21,261.5 48.7%   
Avg. net profit/employee Rs Th-307.9659.1 -46.7%   
INCOME DATA
Net Sales Rs m5,928159,710 3.7%  
Other income Rs m824,766 1.7%   
Total revenues Rs m6,010164,475 3.7%   
Gross profit Rs m84530,973 2.7%  
Depreciation Rs m58513,263 4.4%   
Interest Rs m1,0061,684 59.7%   
Profit before tax Rs m-66420,791 -3.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m995,695 1.7%   
Profit after tax Rs m-76014,924 -5.1%  
Gross profit margin %14.319.4 73.5%  
Effective tax rate %-14.927.4 -54.3%   
Net profit margin %-12.89.3 -137.2%  
BALANCE SHEET DATA
Current assets Rs m5,603124,266 4.5%   
Current liabilities Rs m6,91037,715 18.3%   
Net working cap to sales %-22.054.2 -40.7%  
Current ratio x0.83.3 24.6%  
Inventory Days Days20691 227.1%  
Debtors Days Days8495 88.3%  
Net fixed assets Rs m9,941105,190 9.5%   
Share capital Rs m611,611 3.8%   
"Free" reserves Rs m3,026148,511 2.0%   
Net worth Rs m3,087150,123 2.1%   
Long term debt Rs m5,70738,301 14.9%   
Total assets Rs m16,076239,633 6.7%  
Interest coverage x0.313.3 2.6%   
Debt to equity ratio x1.80.3 724.7%  
Sales to assets ratio x0.40.7 55.3%   
Return on assets %1.56.9 22.1%  
Return on equity %-24.69.9 -247.7%  
Return on capital %3.911.8 33.1%  
Exports to sales %24.034.7 69.2%   
Imports to sales %17.50-   
Exports (fob) Rs m1,42455,419 2.6%   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60057,410 2.8%   
Fx outflow Rs m1,13119,041 5.9%   
Net fx Rs m46938,368 1.2%   
CASH FLOW
From Operations Rs m1,18016,911 7.0%  
From Investments Rs m553-16,687 -3.3%  
From Financial Activity Rs m-1,644-3,487 47.1%  
Net Cashflow Rs m90-3,451 -2.6%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 19, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS